Back to Search
Start Over
Circulating Vascular Endothelial Growth Factor and Soluble fms-Like Tyrosine Kinase-1 as Biomarkers for Endometrial Remodeling Across the Menstrual Cycle.
- Source :
-
Obstetrics and gynecology [Obstet Gynecol] 2021 Jan 01; Vol. 137 (1), pp. 82-90. - Publication Year :
- 2021
-
Abstract
- Objective: To characterize variation in circulating vascular endothelial growth factor (VEGF) and its receptor, soluble fms-like tyrosine kinase-1 (sFLT-1), across the menstrual cycle in normal ovulating women in relation to reproductive hormones to identify the utility of VEGF and sFLT-1 as peripheral biomarkers of endometrial remodeling.<br />Methods: Ninety-six healthy, regularly menstruating ovulatory women, aged 18-44 years, enrolled in the BioCycle Study, a prospective cohort study at a U.S. academic research center. Vascular endothelial growth factor and sFLT-1 were measured in concurrently collected plasma, serum, and urine up to eight times across a single cycle. Reproductive hormones were measured in serum. Mean concentrations of VEGF and sFLT-1 were compared across phases of the cycle, and correlations between specimen types were calculated. Harmonic models estimated associations between VEGF and sFLT-1 and characteristics of hormonal patterns.<br />Results: No variation in VEGF or sFLT-1 levels were detected over the menstrual cycle. Median (25th percentile, 75th percentile) concentrations of VEGF during the menstrual cycle were 31.2 pg/mL (24.1, 56.9) in plasma, 194.1 pg/mL (125.4, 350.2) in serum, and 101.7 pg/mL (64.2, 165.8) in urine. Plasma and serum measures were consistently correlated, whereas urinary measures were not. Vascular endothelial growth factor was not consistently associated with reproductive hormone concentrations, although sFLT-1 was associated with higher mean and amplitude of estradiol.<br />Conclusion: Circulating VEGF and sFLT-1 did not vary across the menstrual cycle and therefore are unlikely to be useful peripheral biomarkers of endometrial changes across the menstrual cycle. For studies measuring circulating VEGF for other reasons, plasma may be the preferred medium and timing to menstrual cycle phase need not be considered for reproductive-age women.<br />Competing Interests: Financial Disclosure Robert M. Silver reports that money was paid to his institution from the NIH and he received funds from Gestavision. Micah J. Hill reports a past role on the Research Advisory Board of Ohana Biosciences, unrelated to present research. The other authors did not report any potential conflicts of interest.<br /> (Copyright © 2020 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Adult
Biomarkers blood
Biomarkers urine
Female
Humans
Menstrual Cycle urine
Prospective Studies
Reference Values
Vascular Endothelial Growth Factor A urine
Vascular Endothelial Growth Factor Receptor-1 urine
Young Adult
Endometrium physiology
Menstrual Cycle blood
Vascular Endothelial Growth Factor A blood
Vascular Endothelial Growth Factor Receptor-1 blood
Subjects
Details
- Language :
- English
- ISSN :
- 1873-233X
- Volume :
- 137
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Obstetrics and gynecology
- Publication Type :
- Academic Journal
- Accession number :
- 33278289
- Full Text :
- https://doi.org/10.1097/AOG.0000000000004171